Conclusion GLP-1 RAs and dual GIP/GLP-1 RAs are highly effective treatment options for T2DM and obesity
Semaglutide activates the GLP-1 receptor, leading to increased insulin production and reduced hepatic glucose output
For general background and systematic reviews see the overview at Healthline and detailed reviews on PubMed Central: PMC review and a trial-focused report PMC trial study
10.1038/nm1196-1254 [DOI] [PubMed] [Google Scholar] Secher, A
58 However, in a Canadian study using data from a large health claims database, comparing the use of a GLP-1 receptor agonist with naltrexone/bupropion to treat obesity, there was an increased risk of pancreatitis
It plays a key role in detoxification, fighting free radicals, and regulating melaninthe pigment responsible for skin color